M&A Deal Summary

ICON Acquires GloboMax

On September 9, 2003, ICON acquired life science company GloboMax for 11M USD

Acquisition Highlights
  • This is ICON’s 5th transaction in the Life Science sector.
  • This is ICON’s 7th largest (disclosed) transaction.
  • This is ICON’s 5th transaction in the United States.
  • This is ICON’s 1st transaction in Maryland.

M&A Deal Summary
Date 2003-09-09
Target GloboMax
Sector Life Science
Buyer(s) ICON
Deal Type Add-on Acquisition
Deal Value 11M USD

Target

GloboMax

Hanover, Maryland, United States
GloboMax LLC is a specialist CRO which provides a range of development and consulting services to the pharmaceutical and biotechnology industries. Company help pharmaceutical and biotech companies successfully develop drug products for the world market while simultaneously achieving distinguished excellence in pharmaceutical sciences and technology.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ICON

Dublin, Ireland
Category Company
Founded 1990
Sector Life Science
Employees41,100
Revenue 8.1B USD (2023)
DESCRIPTION

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. ICON was founded in 1990 and is based in Dublin, Ireland.

DEAL STATS #
Overall 7 of 29
Sector (Life Science) 5 of 16
Type (Add-on Acquisition) 7 of 25
State (Maryland) 1 of 1
Country (United States) 5 of 18
Year (2003) 2 of 2
Size (of disclosed) 7 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-01-24 Medeval Group

United Kingdom

Medeval Group Ltd. is a UK clinical pharmacology group providing Phase I and bioanalytical services to the pharmaceutical and biotechnology industries. Medeval is a specialist provider of Phase I clinical trials, with a strong bias toward the execution of “First-in-man” studies.

Buy $16M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2004-06-01 Beacon Bioscience

Warrington, Pennsylvania, United States

Beacon Bioscience, Inc. is a specialist CRO in the Medical Imaging field. Beacon has a strong technology platform, focused on the centralized management, processing and reading of digitized medical images generated in clinical trials, including X-ray, MRI, CT, PET, Nuclear Medicine and Ultrasound.

Buy -
Mergr

Product

Company

Legal